New academic initiative aims to inform approaches to value assessment frameworks

Holly Campbell   |     May 13, 2016   |   SHARE THIS

As the U. S. health care market continues to shift toward a system that prioritizes and rewards value, there is increasing attention on the development and use of value assessment frameworks. When well-structured and used appropriately, frameworks to assess the value of medical tests, treatments and health care services can be useful in the private market to support patient-centered health care. However, as the number of emerging value frameworks continues to grow, we are seeing great variability in the methods and approaches being used, as well as significant issues related to the process through which frameworks are developed.

To help reduce this inconsistency, The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) recently announced its Initiative on Value Assessment Frameworks to bring together stakeholders across the health care sector to create a set of standards to guide the development of patient-centered value frameworks. The initiative has two phases:

  • Phase I involves identifying and discussing “key methodological and process issues in defining and applying value frameworks.”
  • Phase II convenes a special task force that will produce a white paper advising on “the appropriate definition and use of high-quality value frameworks.”

To kick off phase one, ISPOR issued a call for papers to be included in a special issue on high-quality value assessment of health care interventions in the January 2017 issue of Value in Health. Examples of topics being requested include measurement of value and indirect benefits, incorporating patient-centered outcomes and establishing affordability thresholds, among others.

For more information about the call for papers, please visit the ISPOR website.

Read more about PhRMA’s value assessment principles and why ICER’s model doesn’t meet patients’ needs here.
Holly Campbell

Holly Campbell Holly Campbell is former deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.

Topics: Value-Driven Health Care, Policy Solutions, The Value Collaborative, Value Assessment

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates